As both TFAP2A and HIF‐1 play critical roles in cancer progression, a detailed characterization of their crosstalk could lead to novel therapeutic strategies for targeting and killing cancer cells in hypoxic tumors. The gene discussed is HIF1A; the disease is cancer.